| Objective: To observe the distribution of Bone-derived Murine Mesenchynal Stem (mMSCs) on hyperglycemia state in vivo of the mice, and the differentiation of mMSCs in vivo of diabetic mice, to evaluate the treatment for diabetic mice by mMSCs.Methods: Bone-derived mMSCs were obtained by complete marrow cell culture,and observed under an inverted microscope and certificated by flow cytometry analysis. Use different cell tracing technology, DAPI and GFP, mMSCs were transplant into STZ induced diabetic mice with intravenous. The variation of body weight and the blood glucose were determined respectively after cell transplantation. mMSCs distribution and differentiation and insulin expression in pancreatic tissue were examined by fluorescence microscope and immunohistochemistry.Results: Two weeks after mMSCs transplantation, the mMSCs labeled with DAPI can be detected in lung and liver and pancreatic tissue of the diabetic mice. After four weeks, GFP-mMSCs can be detected in liver and pancreatic tissue. Secretion of murine insulin of mMSCs in pancreatic was detected by IHC. However, the body weight in diabetic mice was not increased, and the average blood glucose levels were still in a high level, there is no significant difference (α=0.05) before and after transplantation. Conclusion: On hyperglycemia state, mMSCs are mainly migrating and colonizing in liver and pancreatic tissue; mMSCs in pancreatic can secrete insulin. This study implies a prospect approach of therapy for Type I diabetes.
|
PDF Full Text Request